Anaplastic lymphoma kinase (ALK) rearrangement, a key oncogenic driver in a small subset of nonsmall cell lung cancers, confers sensitivity to ALK tyrosine kinase inhibitors (TKIs). Crizotinib, a first generation ALK-tKi, has superiority to standard chemotherapy with longer progression-free survival and higher objective response rate. However, clinical benefit is limited by development of resistance, typically within a year of therapy. In this study the combined effect of crizotinib and the MEK inhibitor selumetinib was investigated in both crizotinib naïve (H3122) and crizotinib resistant (CR-H3122) ALKpositive lung cancer cells. Results showed that combination treatment potently inhibited the growth of both H3122 and CR-H3122 cells, resulting from increased apoptosis and decreased cell proliferation as a consequence of suppressed downstream RAS/MApK signalling. the drug combination also elicited a greater than 3-fold increase in Bim, a mediator of apoptosis, and p27, a cyclin dependent kinase inhibitor compared to crizotinib alone. the results support the hypothesis that combining MeK inhibitors with ALK inhibitor can overcome ALK inhibitor resistance, and identifies Bim, PARP and CDK1 as druggable targets for possible triple drug therapy.
unique to ALK-positive NSCLC cells; thus, with a highly specific first target established, the search for secondary targets is facilitated.
One strategy to this search is to investigate mediators of bypass signalling pathways as co-targets for combination with ALK inhibitors. These include receptor tyrosine kinases (RTKs) such as epidermal growth factor receptor (EGFR), insulin like growth factor receptor (IGFR), human epidermal growth factor receptor 2 (HER2) and cKIT, or mutation in EGFR or kirsten rat sarcoma (KRAS). These can regulate downstream signalling independently, promoting the growth and survival of cells irrespective of ALK inhibition [19] [20] [21] [22] [23] [24] [25] . Promisingly, Hrustanovic et al. 26 have demonstrated in vitro and in vivo that targeting MEK together with ALK in cancer cells harbouring EML4-ALK is highly effective at supressing cell growth compared to inhibition of either target alone. Up front combination of ALK and MEK inhibition has improved the response in a preclinical model of EML4-ALK NSCLC, and in a patient derived acquired resistance cellular model of EML4-ALK 26, 27 .
In this study we further investigated dual inhibition of ALK and MEK in ELM4-ALK cells. We aimed to test the hypothesis that combination ALK/MEK inhibition is consistent with independent drug action as described above. We therefore (i.) tested whether the development of ALK inhibitor resistance lead to cross-resistance to MEK inhibition, and (ii.) tested whether combined drug action was greater than that predicted by a model that assumes a common target (the Loewe model 28 ). Finally, we interrogated the pathways by which ALK/MEK inhibition suppressed cancer cell growth so as to identify more druggable targets, as the approach of Bozic et al. requires a combination of three drugs or more to maximise suppression of cancer cell growth and prevention of drug resistance.
We used crizotinib, a first-in-class ALK inhibitor, and selumetinib, a potent, non-ATP competitive inhibitor of marker extraction kernel 1/2 (MEK1/2) which inhibits the phosphorylation of MEK resulting in downregulation of RAS/MAPK signalling 29 . We chose selumetinib because it has demonstrated potent anti-tumour activity in preclinical and clinical trials of various cancers including NSCLC [30] [31] [32] . We investigated the combined effect of crizotinib with selumetinib in both crizotinib naïve and crizotinib resistant ALK-positive lung cancer cells. We confirmed that the combination caused a greater reduction of cell viability compared to single drug treatments, and that this effect was consistent with independent drug action. We also observed, a significant decrease in cell proliferation via G1 arrest and collapse of the S phase, and induction of apoptosis. This led us to determine key roles for Bim, PARP and CDK1, all of which are druggable targets. Our findings therefore add support to the clinical investigation of dual ALK/MEK inhibition therapy as a strategy to delay or overcome drug resistance in ALK-positive lung cancer, and points the way toward possible drug therapies with three or more targets.
Methods and Materials
Materials. Crizotinib and selumetinib were purchased from LC laboratories (Woburn, Massachusetts, USA).
Bovine serum albumin (BSA), Foetal bovine serum (FBS), Rosswell park memorial institute medium (RPMI), penicillin/streptomycin were purchased from Life Technologies (Auckland, New Zealand). Precision plus protein kaleidoscope, acrylamide (1:30) were obtained from Bio-Rad Laboratories (Hercules CA, USA). CL-XPosure film, supersignal west pico were obtained from Thermofisher (Auckland, New Zealand). Propidium iodide was purchased from Sigma-Aldrich (St louis, MO, USA). FxCycle PI/RNase was from Life technologies (California, USA). Annexin V-APC and Ac-DEVD-AFC caspase-3 fluorogenic substrate was purchased from BD Biosciences (New Jersey, USA).
Antibodies against ALK(D5F3), phosphorylated-ALK (Tyr1604), Phospho-p44/42 MAPK (Erk1/2) (Thr202/ Tyr204), Bim, Bcl2, caspase, cleaved caspase, PARP, cleaved PARP, cyclinD1, p27 were purchased from Cell Signaling Technology (Danvers, MA, USA). Erk1/2 and β-tubulin antibodies were purchased from Sigma-Aldrich (St louis, MO, USA). HRP-conjugated goat anti-rabbit and HRP-conjugated goat anti-mouse were obtained from Calbiochem (San Diego, CA, US). cell culture. The human adenocarcinoma ALK-positive non-small cell lung cancer (H3122) cell line harbouring EML4-ALK variant 1 fusion gene was gifted from Professor Daniel Costa, Harvard University. We used this cell line as it contains the most common ELM4-ALK variant (1) which also has good sensitivity to ALK inhibitors 33, 34 . Human adenocarcinoma non-small cell lung cancer (A549) cell line harbouring K-RAS gene codon 12-point mutation were used as a non-ALK control, and were kindly provided by Dr Gregory Giles, University of Otago. Crizotinib-resistant (CR-H3122) cells were generated as described in Wilson et al. 35 and were maintained in 0.8 µM of crizotinib. Briefly, H3122 cells were cultured with increasing concentrations of crizotinib starting from 0.4 µM for 24 h followed by 0.56 µM for next 24 h. Cells were then maintained in 0.80 µM from 3 rd day to 4 months. Media was changed every 2-3 days supplemented with fresh drug.
All cells lines were maintained in RPMI medium supplemented with 100 U/ml of penicillin, 100 μg/ml of streptomycin and 10% (CR-H3122), 5% (H3122), 2% (A549) of fetal bovine serum (FBS). Cells were incubated at 37 °C, 5% CO2, 95% humidified air. cell viability assay. H3122, A549 and CR-H3122 were seeded into 96 wells plate at a density of 7 × 10 3 , 4 × 10 3 and 10 × 10 3 cells per well respectively and incubated for 24 h. Next, cells were treated with indicated concentration of drug and further incubated for 72 h followed by fixation with trichloroacetic acid (TCA). Cell viability was determined using the sulforhodamine B (SRB) assay, as described in Vichai et al. 36 . The concentration of each drug required to reduce the cell viability by 50% (IC 50 ) was determined by nonlinear regression using Graphpad Prism software, from three independent experiments performed in triplicate. cell cycle assay. H3122 (3 × 10 5 cells/well) and CR-H3122 (3.5 × 10 5 cells/well) cells were seeded in 6-well culture plates and incubated for 24 h prior to drug treatment. H3122 cells were treated with indicated concentration of vehicle (DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination. CR-H3122 cells were treated with vehicle (DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7 µM) and their combination. Cells were then incubated for 24 and 48 h. At the end of treatment period, cells were washed with isotonic PBS, collected by trypsinisation and centrifuged. The cell pellets were then fixed with 70% ethanol. Next, cells were washed with ice-cold 0.01 M PBS and centrifuged. Finally, the cell pellet was resuspended in FxCycle PI/RNase staining solution and incubated in the dark for 30 min at room temperature. The samples were then analysed by Gallious BD flow cytometer and data obtained were analysed with FlowJo LLC software. Three independent experiments were performed in triplicate and the results are expressed as cell number in each phase, as a percent of total cell number.
Apoptosis assay. H3122 (3 × 10 5 cells/well) and CR-H3122 (3.5 × 10 5 cells/well) cells were seeded in 6-well culture plates and incubated for 24 h prior to drug treatment. H3122 cells were treated with vehicle (DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination. and incubated for 24, 48 and 72 h. CR-H3122 cells were treated with vehicle (DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7 µM) and their combination followed by incubation for 24 and 48 h. Cells were then washed with 0.01 M PBS, collected by trypsinisation and centrifuged. The cell pellet was resuspended in 100 µl of binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2). Annexin V-APC, propidium iodide (50 µg/ml) and 200 µl of binding solution was added to each sample and incubated in the dark at room temperature. Finally, the samples were analysed on Gallious BD flow cytometer. Data obtained were analysed using Kaluza analysis Software. Three independent experiments were performed in triplicate and the results are expressed as the number of apoptotic cells as a percent of total cell number.
Western blotting. H3122 and CR-H3122 cells were seeded in petri dishes at the density of 2.0 × 10 6 per dish and incubated for 24 h. H3122 cells were treated with indicated concentration of vehicle (DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination. CR-H3122 cells were treated with vehicle (DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7 µM) and their combination. Cells were then incubated for 24 h. Cells were lysed with lysis buffer (50 mM Tris base (pH-7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% NP-40, 0.5% SDS, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 10 mM sodium fluoride, 1 mM PMSF and complete protease and phosphatase inhibitor cocktail). Cells were then collected, sonicated and centrifuged at 14000 rpm for 10 min at 4 °C. 10 µg of protein was subjected to SDS-PAGE and analysed by Western blotting. caspase assay. H3122 (3 × 10 5 cells/well) and CR-H3122 (3.5 × 10 5 cells/well) cells were seeded in 6-well culture plates and incubated for 24 h. H3122 cells were treated with vehicle (DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination for 48 h. CR-H3122 cells were treated with vehicle (DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7 µM) and their combination for 24 h. H3122 and CRH3122 cells were treated with 5 µM and 100 µM of cisplatin (positive control), respectively. Cells were then collected, centrifuged and washed with 0.01 M PBS. Supernatant was discarded and cell pellets were suspended in 100 µl buffer (100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS and 0.0001%NP-40) supplemented with DTT and caspase substrate and further incubated for 30 min at 37 °C. The samples were diluted to 1:5 in buffer (100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS and 0.0001%NP-40) and examined using a spectrofluorometer with excitation and emission wavelengths of 380 and 500 nm, respectively.
Data analysis.
Cell viability data were normalised to control and analysed by nonlinear regression model using Graphpad Prism 7 software. Cell cycle and apoptosis data were analysed using a two-way ANOVA using time as one factor and drug treatment as the other, coupled with a Bonferroni post-hoc test. All other data that did not involve time were analysed using a one-way ANOVA coupled with a Bonferroni post-hoc test. Data are presented as the mean ± SEM. P < 0.05 was the minimal requirement for a statistically significant difference.
To determine if crizotinib and selumetinib suppress cell growth in a manner consistent with independent drug action in both H3122 and CR-H3122 cells, we modelled combination treatment data by calculating the combination index (CI) described by Chou and Talalay 37 using CompuSyn software. Commonly used in the study of drug synergy (positive interaction), this approach is derived from the zero-interaction (additivity) model of Loewe. This model is based on the assumption of a shared target for two drugs. Therefore, an effect greater than predicted by Loewe additivity (Chou-Talaly CI < 1) means that central assumption of the Loewe model is falsified; thus, that the drugs act on separate drug targets. Determining whether drugs that act on separate targets have a positive interaction (synergy) requires a different zero-interaction model (the Bliss model) 38 . We did not carry out this analysis, as testing for independent drug action rather than synergy was our aim.
Results crizotinib in combination with selumetinib suppression of the growth of ALK-positive nScLc cells.
The relative potency of crizotinib and selumetinib was initially examined in ALK-positive (H3122) and ALK-negative (A549) non-small cell lung cancer cells. H3122 cells were highly sensitive to crizotinib compared to selumetinib, with cell viability IC 50 values of 0.1 and 3 µM, respectively ( Fig. 1A ). Sensitivity to crizotinib by ALKnegative A549 cells was markedly less than for ALK-positive cells, (IC 50 of 0.8 µM). IC 50 values for selumetinib were similar in A549 cells as in H1322 cells (2 µM) (Fig. S1A ). The effect of crizotinib and selumetinib in combination was then examined in H3122 and A549 cells. Six different combinations were selected using equivalent potencies relative to each drug's IC 50 value. For each concentration, the two drugs alone were compared with the combination of the two. Chou-Talalay analysis was performed to determine if the two drugs acted greater than Loewe additivity 37 . In H3122 cells, 3 of the 6 drug combinations examined significantly reduced cell viability compared to both single drug treatments (p < 0.05) ( Fig. 1B ) and all drug combinations showed greater than Loewe additivity (Chou-Talalay Combination index < 1) (Fig. 1C) . By contrast, the combined effect of crizotinib and selumetinib was solely driven by selumetinib in A549 cells ( Supplementary Fig. S1B ). Furthermore, combination www.nature.com/scientificreports www.nature.com/scientificreports/ indices showed that all combinations except the higher concentration of the drugs were mutually antagonistic (CI > 1) ( Supplementary Fig. S1C ).
Effect of crizotinib and selumetinib combination treatment on downstream signalling pathway and cell cycle mediators.
To investigate the mechanisms involved in suppression of cell growth by the combination treatment, key proteins downstream of the RAS/MAPK signalling pathway were examined. Western blotting was performed to determine the expression and activation of ALK and MEK, by measuring ALK, phosphorylated-ALK (pALK), ERK and phosphorylated-ERK (pERK). After 24 hours, pALK/ALK was decreased 90% by both crizotinib alone and the combination of crizotinib and selumetinib, whereas there was no change following selumetinib (Fig. 2B) . Additionally, pERK/ERK was reduced 64% by crizotinib, 95% by selumetinib, and 99% by the drugs in combination (p < 0.05) (Fig. 2C) .
The impact of combination treatment on cell cycle progression was then investigated. Cell cycle analysis showed that both crizotinib and selumetinib as single drug treatments promoted the accumulation of H3122 cells in the G1 phase of the cell cycle. Combination of the two drugs increased the percentage of cells in the G1 phase even further. This was accompanied by suppression of the number of S phase cells by greater than 77% compared to either of the single drug treatments (p < 0.05) (Fig. 2D) . Therefore, the expression of proteins involved in the G1 to S phase transition such as cyclin D1 and the cyclin dependent kinase inhibitor, p27, were examined using Western blotting. Combination drug treatment significantly decreased the protein expression of cyclin D1 (>80%) compared to single drug treatments ( Fig. 2E ). Moreover, the expression level of p27 was markedly increased by 4-and 1.3-fold by the combination treatment compared to crizotinib or selumetinib alone (p < 0.05) crizotinib and selumetinib combine to induce mediators of apoptosis. Crizotinib also exhibits anti-tumour activity via induction of apoptosis (Christensen et al., 2007) . Similarly, selumetinib, a potent MEK1/2 inhibitor, downregulates the RAS/MAPK signalling pathway leading to activation of downstream apoptotic signalling 39 . Therefore, whether the combination of crizotinib with selumetinib could enhance induction www.nature.com/scientificreports www.nature.com/scientificreports/ of apoptosis in H3122 cells was investigated. Following drug treatment, apoptosis was initiated at 24 h, reached maximum at 48 h and entered late apoptotic phase at 72 h (Fig. 3A) . After 48 h, the percentage of apoptotic H3122 cells was only slightly increased by crizotinib or selumetinib treatment (4 or 7%, respectively), whereas the combination treatment resulted in significant increase in the percentage of apoptotic cells (17%) (p < 0.05). To determine the drivers of apoptosis, the expression of key regulators of intrinsic apoptosis Bim, Bcl2, cleaved caspase, and cleaved PARP were examined by Western blotting. Combination treatment significantly increased the endogenous expression of Bim by 3 and 0.3-fold, respectively compared to crizotinib and selumetinib alone (p < 0.05). However, there was no change in Bcl2 expression ( Supplementary Fig. S2B ). After 24 h of drug treatment, cleaved caspase expression was negligible but was significantly increased after 48 h of combination treatment (Fig. 3D) . This observation is consistent with results from apoptosis assay suggesting that induction of apoptosis was maximal after 48 h of treatment. Combination treatment significantly increased cleaved caspase expression by 3 to 7-fold compared to either drug alone. To confirm this, we carried out a caspase assay, and found sharp increase in caspase activity with combination treatment consistent with result from Western blotting ( Supplementary  Fig. S2C ). Expression of cleaved PARP was markedly increased by 8 to 26-fold from combination compared to either drug alone (p < 0.05) (Fig. 3E) . These results show that the combination of crizotinib and selumetinib significantly increased apoptosis by increasing the expression of Bim, cleaved caspase and cleaved PARP to a degree that not reached by crizotinib alone.
Effect of combination of crizotinib and selumetinib in crizotinib resistant ALK-positive NSCLC cells.
The anti-proliferative effect of crizotinib or selumetinib and their combination was then examined in crizotinib resistant ALK-positive NSCLC cells (CR-H3122) 35 . Sensitivity of CR-H3122 cells to crizotinib was highly reduced compared to H3122 cells, with an IC 50 of 2.3 µM (22-fold over parental H3122 cells). The IC 50 for selumetinib was elevated in CR-H1322 cells to 11 µM, a 3-fold increase compared to H3122 (Fig. 4A) . Results from combination drug treatment showed that all six combinations significantly supressed the growth of CR-H3122 cells compared to single drug treatment (p < 0.05) (Fig. 4B) . Interestingly, combination crizotinib with selumetinib was highly potent in the resistant cells compared to the parental H3122 cells (Chou-Talaly Combination Indices < 0.3) ( Fig. 4C) .
To further evaluate the mechanisms for the drug combination effects on crizotinib resistant cells, proteins downstream of the RAS/MAPK signalling pathway, cell cycle progression and apoptosis were all examined. Crizotinib alone had almost no effect on the phosphorylation of ALK and ERK in CR-H1322 cells, consistent with ALK inhibitor resistance. Nor was there any significant reduction of ALK phosphorylation by combination of crizotinib with selumetinib ( Fig. 5B) . However, the cells remained sensitive to ERK phosphorylation by selumetinib, with a 93% decrease in pERK/ERK protein expression after 24 h. Moreover, the combination of crizotinib and selumetinib decreased the protein expression of pERK/ERK by 99% (p < 0.05).
Cell cycle analysis showed that after 24 and 48 h the combination treatment significantly increased the percentage of cells arrested in the G1 phase compared to crizotinib (p < 0.05) (Fig. 5A) . Similarly, apoptosis assay showed that combination treatment significantly increased the percentage of early apoptotic cells (18%) compared to crizotinib (8%) or selumetinib (5%) after 24 h (p < 0.05) (Fig. 6A) . Lastly, Western blotting was performed to determine the expression of cyclin D1, p27, Bim, Bcl2, cleaved caspase and cleaved PARP. Combination treatment significantly increased the expression of p27, Bim, cleaved caspase and cleaved PARP by 1.83, 12, 0.3, 0.9-fold, respectively, whereas, cyclin D1 was decreased by 1-fold. Similar to what was observed in H3122 cells, there was no change in expression of Bcl2 compared to crizotinib (p < 0.05) (Figs. 5E,F, 6C-E and S3C)
Discussion
The identification of an ALK-rearrangement oncogene as a therapeutic target and the development of potent ALK tyrosine kinase inhibitors (TKIs) has revolutionised treatment for ALK-positive patients 40 . But despite initial responses, complete and lasting response to ALK-TKI monotherapy is rare to non-existent, as patients typically relapse within a few years at most 41 . Overcoming ALK inhibitor resistance is therefore an area of major research effort. Combination therapy targeting primary oncoproteins and their critical effectors can be an effective alternative therapy that can overcome acquired resistance and improve therapeutic efficacy. The MAPK pathway has been identified as one such key bypass mediator for ALK-positive NSCLC 26 . Building on the work of Hrustanovic et al. 26 we focused on the MAPK pathway; targetting MEK, which is an early mediator upstream of ERK but downstream of ALK and other RTKs. We further found that the combination of crizotinib and selumetinib inhibited cell viability in H3122 cells to a greater extent than predicted by Loewe additivity; importantly this property was found to an even greater degree in crizotinib resistant CR-H1322 cells. This supports the use of combination drug treatment over sequential treatment. By contrast, in an earlier study, we found that the combination of an IGF-1R inhibitor with crizotinib was no more effective in our crizotinib resistant cells than switching to the IGF-1R inhibitor alone 35 .
Our results leave open the question of whether to start combination therapy at the beginning of treatment, or only after the development of resistance to crizotinib. Upfront combination theory is supported by the work of Bozic et al. 17, 18 who concluded that simultaneous combination treatment can be more effective than sequential therapy in delaying the emergence of mutations or combinations of mutations that confer resistance to both drugs 17 . Thus, an upfront combination of the two drugs could suppress the accumulation of mutations and ultimately extend the time to relapse. However, as we found that the development of crizotinib resistance caused a small but statistically significant cross-resistance to selumetinib in ELM4-ALK-positive cells (IC 50 values of crizotinib and selumetinib were increased by 22-and 3-fold, respectively, compared to parental H3122 cells), our results do not support the hypothesis that there are no mutations that may cause cross resistance between these two drug targets. www.nature.com/scientificreports www.nature.com/scientificreports/ We have not yet determined the precise mechanisms of resistance in CR-H1322 cells. We have previously shown that proteins such as SRC are upregulated in these cells, and that constitutive phosphorylation of ALK is also upregulated 35 . We have now sequenced the ALK kinase domains in both H3122 and CR-H3122 cells and have found no differences between them ( Supplementary Tables 1 and 2 ). We hypothesise that ALK activation is dysregulated or ALK copy number is increased in CR-H3122 cells, and are currently carrying out whole genome analysis to investigate these hypotheses.
Our approach adds to the findings of Hrustanovic et al. 26 who found that combination ALK/MEK inhibition prevented the emergence of resistance in preclinical models of ALK-positive NSCLC 26 . The authors show that is because of re-activation of the RAS/MAPK pathway via diverse mechanisms of resistance (re-activation of ALK as well as activation of oncogenes such as EGFR, IGFR, HER2, cKIT) [19] [20] [21] [22] [23] [24] [25] [26] . Our investigations of the signalling pathways underlying mechanisms showed that the drug combination leads to a strong downregulation of the RAS/ MAPK signalling pathway that in turn promotes both cell cycle arrest and apoptosis. In H3122 and CR-H3122 cells, combination treatment significantly decreased the protein phosphorylation of pERK/ERK compared to crizotinib as a single drug treatment. Both crizotinib and selumetinib are known to exhibit anti-tumour activity via G1 cell cycle arrest and induction of apoptosis in various cancers including NSCLC [42] [43] [44] and their combination further increased this G1 phase arrest and suppression of the S phase. Further experiments showed that this is in part mediated by decrease in the expression of cyclin D1 and an increase in the expression of p27. Consistent with this, the RAS/MAPK pathway is involved in the regulation of G1 cell cycle proteins. Phosphorylation of ERK leads to migration to the nucleus and activation of cyclin D1 and downregulation of p27. Thus, ERK plays an important role for entry into the S phase of the cell cycle 45 .
Combination treatment also significantly increased apoptosis compared to individual drugs in both crizotinib naïve and crizotinib resistant ALK-positive NSCLC cells. Specifically, cleaved caspase and cleaved PARP were markedly increased following combination treatment, which was mediated by Bim, a pro-apoptotic protein in the Bcl2 family (though Bcl2 itself was not changed). Both crizotinib and selumetinib individually increased the www.nature.com/scientificreports www.nature.com/scientificreports/ expression of Bim which is consistent with other studies in B-cell lymphoma and NSCLC cells 46, 47 . The mechanism behind the increase in expression of Bim is associated with a decrease in the phosphorylation of ERK, as it is well known that the RAS/MAPK signalling pathway phosphorylates Bim and promotes its proteasomal degradation thereby supressing apoptosis 48 . Similarly, a significant increase in cleaved caspase and cleaved PARP was observed in CR-H3122 cells following combination treatment. This effect was driven mostly by crizotinib where the contribution of selumetinib was minimal. Following selumetinib treatment, apoptosis was a Bim-dependent 
